Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| George Davis | M | 53 | 20 years | |
| Elaine Heron | M | 76 | 22 years | |
| Brian Mueller | M | 50 | 22 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kim Tsuchimoto | F | 61 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 18 years |
| Grant W. Denison | M | - | - | |
| Pierre LaPalme | M | 83 | 12 years | |
| Mark Wood | M | 57 | 9 years | |
| Fredric D. Price | M | 78 | 4 years | |
| Louis C. Drapeau | M | 79 | 3 years | |
| Sandra Shpilberg | F | 48 | 9 years | |
| Christopher Starr | M | 71 | 9 years | |
| Joshua Grass | M | - | 14 years | |
| Raymond Anderson | M | 82 | 4 years | |
| Robert A. Heft | M | 69 | 3 years | |
| Patrice Rioux | M | 73 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 5 years |
| Steven Jungles | M | 58 | - | |
| John Urquhart | M | - | - | |
| Amy Lea Waterhouse | F | - | - | |
| Karl Cahill | M | 51 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | - |
| Vimal Srivastava | M | 58 | 2 years | |
| Alejandro Dorenbaum | M | 64 | 7 years | |
| Dan Oppenheimer | M | - | 14 years | |
| John Ditton | M | 60 | 2 years | |
| Stuart J. Swiedler | M | 68 | - | |
| Matt Patterson | M | 52 | 6 years | |
| Craig Johnson | M | 62 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 1 years |
| Franz L. Cristiani | M | 83 | - | |
| Robert Baffi | M | 68 | 20 years | |
| Vijay Samant | M | 77 | 2 years | |
| Erich Sager | M | 66 | 9 years | |
| Emil Kakkis | M | 63 | 11 years | |
| John C. Klock | M | 79 | - | |
| Ansbert Gadicke | M | 66 | 4 years | |
| David Scott Geyer | M | 65 | 1 years | |
| Jeffrey Cooper | M | 68 | 9 years | |
| Min MIn Qin | M | 66 | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 36 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Todd C. Zankel
- Personal Network
